New one-year data suggests transseptal MViV with a Sapien 3 heart valve is a "favorable and safe procedure." Researchers plan to follow patients for a total of 10 years.

Researchers described pharmacies as an “attractive setting for community-based AFib screening."

FibriCheck has been increasing its presence in the United States in anticipation of this approval, opening a new office and partnering with U.S. hospitals. 

Sahil Parikh, MD, director of endovascular services, New York-Presbyterian, explains details from the big-data REAL-PE study comparing mechanical thrombectomy to ultrasound assisted catheter thrombolysis.

Major complications are rare during percutaneous coronary intervention. When they do occur, however, the in-hospital mortality rate is relatively high. 

Researchers tracked SWEDEHEART data from more than 8,000 TAVR patients treated from 2008 to 2022. Overall, they said, PPM after TAVR was rare, and its impact on outcomes was "negligible."

Under this new arrangement, Volta Medical's AI software will be integrated into GE Healthcare offerings to improve AFib outcomes. 

Physicians and researchers complete thousands of clinical trials each year, but some findings prove far more significant than others. For cardiologist Dharmesh Patel, MD, the results of the SMART trial have changed the way he’s managing and recommending treatment for women with symptomatic severe aortic stenosis.